51135-70-7

Basic information

• Product Name: 5-METHYL-PYRAZOLO[1,5-A]PYRIDINE-3-CARBOXYLIC ACID ETHYL ESTER
• Synonyms: 5-METHYL-PYRAZOLO[1,5-A]PYRIDINE-3-CARBOXYLIC ACID ETHYL ESTER;ETHYL 5-METHYLPYRAZOLO[1,5-A]PYRIDINE-3-CARBOXYLATE
• CAS NO: 51135-70-7
• Molecular Formula: C₁₁H₁₂N₂O₂
• Molecular Weight: 204.23
• Mol File: 51135-70-7.mol

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 5-METHYL-PYRAZOLO[1,5-A]PYRIDINE-3-CARBOXYLIC ACID ETHYL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: 5-METHYL-PYRAZOLO[1,5-A]PYRIDINE-3-CARBOXYLIC ACID ETHYL ESTER(51135-70-7)
• EPA Substance Registry System: 5-METHYL-PYRAZOLO[1,5-A]PYRIDINE-3-CARBOXYLIC ACID ETHYL ESTER(51135-70-7)

Safety Data

• Hazardous Substances Data: 51135-70-7(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
5-Methyl-pyrazolo[1,5-a]pyridine-3-carboxylic acid ethyl ester is used as an anti-cancer agent for its ability to inhibit the activity of CDK1 and CDK2, key enzymes involved in cell cycle regulation. This inhibition leads to the suppression of cancer cell proliferation and the induction of cell cycle arrest, making it a valuable compound for the treatment of various types of cancer.
Used in Cancer Research:
In the field of cancer research, 5-Methyl-pyrazolo[1,5-a]pyridine-3-carboxylic acid ethyl ester serves as a valuable tool for studying the mechanisms of cell cycle regulation and the development of novel cancer therapeutics. Its selective inhibition of CDK1 and CDK2 provides insights into the role of these kinases in cancer progression and offers a basis for designing new drugs targeting these enzymes.
Used in Drug Development:
5-Methyl-pyrazolo[1,5-a]pyridine-3-carboxylic acid ethyl ester is utilized in the development of new pharmaceuticals targeting cancer treatment. Its unique chemical structure and mechanism of action provide a foundation for the creation of innovative drugs that can effectively combat cancer by disrupting the cell cycle and preventing the uncontrolled growth of cancer cells.
Used in Drug Screening:
In the process of drug screening, 5-Methyl-pyrazolo[1,5-a]pyridine-3-carboxylic acid ethyl ester is employed as a reference compound to evaluate the potency and selectivity of other potential CDK inhibitors. This helps in the identification of new compounds with similar or improved anti-cancer properties, contributing to the advancement of cancer therapeutics.
Used in Combination Therapy:
5-Methyl-pyrazolo[1,5-a]pyridine-3-carboxylic acid ethyl ester is considered for use in combination therapy with other anti-cancer agents to enhance the overall efficacy of cancer treatment. Its ability to induce cell cycle arrest and inhibit cancer cell proliferation can be synergistic with other treatments, potentially overcoming drug resistance and improving patient outcomes.

Upstream product

• 51135-56-9 1-amino-4-methylpyridin-1-ium 2,4,6-trimethylbenzene sulfonate 
• 623-47-2 propynoic acid ethyl ester 
• 108-89-4 picoline 
• 38202-27-6 ethyl O-(2-mesitylenesulfonyl)acetohydroxamate 
• 105-37-3 Ethyl propionate 
• 13061-96-6 dihydroxy-methyl-borane 
• 885276-93-7 ethyl 5-bromopyrazolo[1,5-a]pyridine-3-carboxylate 

Downstream Products

• 143803-80-9 5-methylpyrazolo[1,5-a]pyridine-3-carboxylic acid 
• 1101118-06-2 N,2-dimethyl-N'-((5-methylpyrazolo[1,5-a]pyridin-3-yl)-methylene)-5-nitrobenzenesulfonohydrazide 

Relevant articles and documents

Design, synthesis and biological evaluation of ring-fused pyrazoloamino pyridine/pyrimidine derivatives as potential FAK inhibitors

We report herein the synthesis of novel ring-fused pyrazoloamino pyridine/pyrimidine derivatives as potential FAK inhibitors and the evaluation of pharmaceutical activity against five cancer cell lines (MDA-MB-231, BXPC-3, NCI-H1975, DU145 and 786O). Generally, the majority of compounds displayed strong anti-FAK enzymatic potencies (IC50 1 nM) and could effectively inhibit several class of cancer cell lines within the concentration of 3 μM in comparison with GSK2256098 as a reference. Among them, compound 4o is considered to be the most effective due to high sensitivity in antiproliferation. In culture, 4o could not only inhibit FAK Y397 phosphorylation in MDA-MB-231 cell line, but also trigger apoptosis in a dose-dependent manner. Furthermore, computational docking analysis also suggested that 4o and TAE-226 displayed the similar interaction with FAK kinase domain.

COMBINATION PHARMACEUTICAL AGENTS AS RSV INHIBITORS

The present invention relates to pharmaceutical agents administered to a subject either in combination or in series for the treatment of a Respiratory Syncytial Virus (RSV) infection, wherein treatment comprises administering a compound effective to inhibit the function of the RSV and an additional compound or combinations of compounds having anti-RSV activity.

Focal adhesion kinase inhibitor and use

The invention belongs to the field of medicines, relates to a focal adhesion kinase inhibitor and use, in particular relates to a novel focal adhesion kinase inhibitor compound, or stereoisomers, geometric isomers, tautomers, oxynitrides, hydrates, solvates, metabolites, pharmaceutically acceptable salts or prodrugs thereof, further relates to the use of the compound and pharmaceutical compositions as medicines, in particular the use of the compound and pharmaceutical compositions in manufacture of medicines for treatment or prevention of cancer, pulmonary hypertension, and pathological angiogenesis-related diseases.

BENZODIAZEPINE DERIVATIVES AS RSV INHIBITORS

The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit Respiratory Syncytial Virus (RSV). The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from RSV infection. The invention also relates to methods of treating an RSV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

2-(PYRAZOLOPYRIDIN-3-YL)PYRIMIDINE DERIVATIVES AS JAK INHIBITORS

New 2-(pyrazolopyridin-3-yl)pyrimidine derivatives are disclosed; as well as process for their preparation, pharmaceutical compositions comprising them and their use in therapy as inhibitors of Janus Kinases (JAK).

PYRAZOLOPYRIMIDIN-2-YL DERIVATIVES AS JAK INHIBITORS

New pyrazolopyridmiin-2-yl derivatives are disclosed; as well as process for their preparation, pharmaceutical compositions comprising them and their use in therapy as inhibitors of Janus Kinases (JAK).

HETEROCYCLIC COMPOUND

The present invention provides a compound or a salt thereof useful for an agent for the prophylaxis or treatment of neurodegenerative disease and the like. The present invention relates to a compound represented by the formula wherein each symbol is as defined in the present specification, or a salt thereof.

Discovery of pyrazolo[1,5-a]pyridines as p110α-selective PI3 kinase inhibitors

We have made a novel series of pyrazolo[1,5-a]pyridines as PI3 kinase inhibitors, and demonstrated their selectivity for the p110α isoform over the other Class Ia PI3 kinases. We investigated the SAR around the pyrazolo[1,5-a]pyridine ring system, and found compound 5x to be a particularly potent example (p110α IC50 0.9 nM). This compound inhibits cell proliferation and phosphorylation of Akt/PKB, a downstream marker of PI3 kinase activity, and showed in vivo activity in an HCT-116 human xenograft model.

PYRAZOLO[1,5-A]PYRIDINES AND THEIR USE IN CANCER THERAPY

Pyrazolo[1,5-a]pyridines are described, including methods for their preparation, and their use as agents or drugs for cancer therapy, both alone or in combination with radiation and/or other anticancer drugs.

Pyrazolo[1,5-a]pyridine-3-carboxylic acid derivatives and their pharmaceutical use

Described herein are pyrazolo[1,5-a]pyridine-3-carboxylic acid derivatives represented by the following formula (I): STR1 wherein R 1 and R 2 individually mean a hydrogen atom or a lower alkyl group, R 3 denotes an azabicyclo group containing a tertiary nitrogen atom, and Y stands for --O-- or --NH--, or salts thereof. Their preparation process and serotonin receptor antagonists containing them as active ingredients are also described.